Pharmaxis Announces Milestone in Phase 3 Trial for Bronchiectasis
Release Date: 08/03/2013 12:00am
Specialty pharmaceutical company Pharmaxis (ASX: PXS) today announced formal completion of a 52 week, Phase 3 international trial assessing the effectiveness of Bronchitol®in people with bronchiectasis. The last participant has completed the final clinical visit in the trial which began in October 2009.
Categories: News and Media